Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges.
Tahani TabassumAhsab RahmanYusha ArafBishajit SarkarMohammad Jakir HosenPublished in: Beni-Suef University journal of basic and applied sciences (2022)
Taking asthma as an increased risk factor for COVID-19 morbidity, this article aims to provide comprehensive insights into the risk and proper management of asthma patients during this COVID-19 pandemic. The common medications of asthma patients suppress their respiratory immune response that might facilitate cytokine storm in COVID-19 patients. Similarly, there are risks of viral-induced asthma exacerbations. Besides, different social issues such as shortage of medicines, SDOH, and delayed clinical trials put asthma patients through inconvenience. The primary focus at this point should be to reduce probable asthma attacks and severity to prevent hospitalization of asthma patients. Moreover, for better management of asthma patients maintaining an asthma action plan and healthy lifestyle, ensuring a nutritious diet, and developing self-management interventions can play a crucial role.
Keyphrases
- chronic obstructive pulmonary disease
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- lung function
- clinical trial
- immune response
- prognostic factors
- sars cov
- physical activity
- cardiovascular disease
- coronavirus disease
- metabolic syndrome
- allergic rhinitis
- type diabetes
- healthcare
- cystic fibrosis
- patient reported outcomes
- air pollution
- stress induced
- respiratory syndrome coronavirus